{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T23:25:59Z","timestamp":1793834759802,"version":"4.6.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1038\/s41440-026-02802-6","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T07:02:00Z","timestamp":1788418920000},"page":"3046-3057","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Effect of sacubitril\/valsartan on serum uric acid and blood pressure in patients with hypertension and asymptomatic hyperuricemia: A randomized clinical trial"],"prefix":"10.1038","volume":"49","author":[{"given":"Meng-Bo","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong-Cong","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Liang","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Tong","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Bing","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bi-Ming","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing-Hua","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Fei","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,3]]},"reference":[{"key":"2802_CR1","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1024\/0040-5930\/a000770","volume":"73","author":"K Murray","year":"2016","unstructured":"Murray K, Burkard T. [Hyperuricemia, gout and cardiovascular diseases]. Ther Umsch. 2016;73:141\u20136.","journal-title":"Ther Umsch"},{"key":"2802_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-025-23139-8","volume":"25","author":"C Wang","year":"2025","unstructured":"Wang C, Tavengana G, Mei W, Fang Y, Hu J, Ren X, et al. Investigating the relationship between body mass index, hypertension, and new-onset hyperuricemia in a Chinese repeat health checkup population. BMC Public Health. 2025;25:1899.","journal-title":"BMC Public Health"},{"key":"2802_CR3","doi-asserted-by":"publisher","first-page":"27","DOI":"10.21037\/atm-20-3458","volume":"9","author":"J Liu","year":"2021","unstructured":"Liu J, Chen L, Yuan H, Huang K, Li G, Sun N, et al. Survey on uric acid in Chinese subjects with essential hypertension (SUCCESS): a nationwide cross-sectional study. Ann Transl Med. 2021;9:27.","journal-title":"Ann Transl Med"},{"key":"2802_CR4","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/7545137","volume":"2019","author":"X Lin","year":"2019","unstructured":"Lin X, Wang X, Li X, Song L, Meng Z, Yang Q, et al. Gender- and Age-Specific Differences in the Association of Hyperuricemia and Hypertension: A Cross-Sectional Study. Int J Endocrinol. 2019;2019:7545137.","journal-title":"Int J Endocrinol"},{"key":"2802_CR5","doi-asserted-by":"publisher","first-page":"e114259","DOI":"10.1371\/journal.pone.0114259","volume":"9","author":"J Wang","year":"2014","unstructured":"Wang J, Qin T, Chen J, Li Y, Wang L, Huang H, et al. Hyperuricemia and risk of incident hypertension: a systematic review and meta-analysis of observational studies. PLoS One. 2014;9:e114259.","journal-title":"PLoS One"},{"key":"2802_CR6","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1080\/14740338.2020.1836151","volume":"19","author":"C Borghi","year":"2020","unstructured":"Borghi C, Soldati M, Bragagni A, Cicero AFG. Safety implications of combining ACE inhibitors with thiazides for the treatment of hypertensive patients. Expert Opin Drug Saf. 2020;19:1577\u201383.","journal-title":"Expert Opin Drug Saf"},{"key":"2802_CR7","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1038\/s41440-024-01762-z","volume":"47","author":"K Kario","year":"2024","unstructured":"Kario K, Ohbayashi H, Hashimoto M, Itabashi N, Kato M, Uchiyama K, et al. Home blood pressure-lowering effect of a non-steroidal mineralocorticoid receptor blocker, esaxerenone, versus trichlormethiazide for uncontrolled hypertension: the EXCITE-HT randomized controlled study. Hypertens Res. 2024;47:2435\u201346.","journal-title":"Hypertens Res"},{"key":"2802_CR8","doi-asserted-by":"publisher","first-page":"3736","DOI":"10.1016\/j.transproceed.2009.06.225","volume":"41","author":"X Zhu","year":"2009","unstructured":"Zhu X, Chen J, Han F, Cheng M, Xu L, Zhang L, et al. Efficacy and safety of losartan in treatment of hyperuricemia and posttransplantation erythrocytosis: results of a prospective, open, randomized, case-control study. Transpl Proc. 2009;41:3736\u201342.","journal-title":"Transpl Proc"},{"key":"2802_CR9","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/1475-2840-12-159","volume":"12","author":"Y Nishida","year":"2013","unstructured":"Nishida Y, Takahashi Y, Susa N, Kanou N, Nakayama T, Asai S. Comparative effect of angiotensin II type I receptor blockers on serum uric acid in hypertensive patients with type 2 diabetes mellitus: a retrospective observational study. Cardiovasc Diabetol. 2013;12:159.","journal-title":"Cardiovasc Diabetol"},{"key":"2802_CR10","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1161\/HYPERTENSIONAHA.116.08556","volume":"69","author":"B Williams","year":"2017","unstructured":"Williams B, Cockcroft JR, Kario K, Zappe DH, Brunel PC, Wang Q, et al. Effects of Sacubitril\/Valsartan Versus Olmesartan on Central Hemodynamics in the Elderly With Systolic Hypertension: The PARAMETER Study. Hypertension. 2017;69:411\u201320.","journal-title":"Hypertension"},{"key":"2802_CR11","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1093\/ajh\/hpx111","volume":"30","author":"O Supasyndh","year":"2017","unstructured":"Supasyndh O, Wang J, Hafeez K, Zhang Y, Zhang J, Rakugi H. Efficacy and Safety of Sacubitril\/Valsartan (LCZ696) Compared With Olmesartan in Elderly Asian Patients (\u226565 Years) With Systolic Hypertension. Am J Hypertens. 2017;30:1163\u20139.","journal-title":"Am J Hypertens"},{"key":"2802_CR12","doi-asserted-by":"publisher","first-page":"24","DOI":"10.14740\/cr813","volume":"10","author":"R De Vecchis","year":"2019","unstructured":"De Vecchis R, Soreca S, Ariano C. Anti-Hypertensive Effect of Sacubitril\/Valsartan: A Meta-Analysis of Randomized Controlled Trials. Cardiol Res. 2019;10:24\u201333.","journal-title":"Cardiol Res"},{"key":"2802_CR13","first-page":"603","volume":"32","author":"Chinese Hypertension Prevention and Treatment Guidelines Revision Committee","year":"2024","unstructured":"Chinese Hypertension Prevention and Treatment Guidelines Revision CommitteeHypertension Alliance (China), China Healthcare International Exchange Promotion Association Hypertension Branch, et al. Chinese Hypertension Prevention and Treatment Guidelines (2024 Revision). Chin J Hypertens. 2024;32:603\u2013700.","journal-title":"Chin J Hypertens"},{"key":"2802_CR14","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1002\/ejhf.1056","volume":"20","author":"UM Mogensen","year":"2018","unstructured":"Mogensen UM, K\u00f8ber L, Jhund PS, Desai AS, Senni M, Kristensen SL, et al. Sacubitril\/valsartan reduces serum uric acid concentration, an independent predictor of adverse outcomes in PARADIGM-HF. Eur J Heart Fail. 2018;20:514\u201322.","journal-title":"Eur J Heart Fail"},{"key":"2802_CR15","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1002\/ejhf.1984","volume":"22","author":"S Selvaraj","year":"2020","unstructured":"Selvaraj S, Claggett BL, Pfeffer MA, Desai AS, Mc Causland FR, McGrath MM, et al. Serum uric acid, influence of sacubitril-valsartan, and cardiovascular outcomes in heart failure with preserved ejection fraction: PARAGON-HF. Eur J Heart Fail. 2020;22:2093\u2013101.","journal-title":"Eur J Heart Fail"},{"key":"2802_CR16","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1007\/s00380-016-0796-z","volume":"31","author":"M Masaki","year":"2016","unstructured":"Masaki M, Mano T, Eguchi A, Fujiwara S, Sugahara M, Hirotani S, et al. Long-term effects of L- and N-type calcium channel blocker on uric acid levels and left atrial volume in hypertensive patients. Heart Vessels. 2016;31:1826\u201333.","journal-title":"Heart Vessels"},{"key":"2802_CR17","first-page":"1","volume":"36","author":"Chinese Society of Endocrinology, Chinese Medical Association","year":"2020","unstructured":"Chinese Society of Endocrinology, Chinese Medical AssociationChinese Guidelines for the Diagnosis and Treatment of Hyperuricemia and Gout (2019) [J]. Chin J Endocrinol Metah. 2020;36:1\u201313.","journal-title":"Chin J Endocrinol Metah"},{"key":"2802_CR18","doi-asserted-by":"publisher","first-page":"2937","DOI":"10.1681\/ASN.2006040368","volume":"17","author":"YC Ma","year":"2006","unstructured":"Ma YC, Zuo L, Chen JH, Luo Q, Yu XQ, Li Y, et al. Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. J Am Soc Nephrol. 2006;17:2937\u201344.","journal-title":"J Am Soc Nephrol"},{"key":"2802_CR19","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1097\/MBP.0000000000000725","volume":"29","author":"T Horio","year":"2024","unstructured":"Horio T, Iwashima Y, Yoshiyama M, Fukuda D, Hasegawa T, Fujimoto K. Serum uric acid-lowering effect of sacubitril\/valsartan in hypertensive patients: evaluation by switching from angiotensin II receptor blockers. Blood Press Monit. 2024;29:305\u201311.","journal-title":"Blood Press Monit"},{"key":"2802_CR20","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1172\/JCI112368","volume":"77","author":"P Weidmann","year":"1986","unstructured":"Weidmann P, Hasler L, Gn\u00e4dinger MP, Lang RE, Uehlinger DE, Shaw S, et al. Blood levels and renal effects of atrial natriuretic peptide in normal man. J Clin Invest. 1986;77:734\u201342.","journal-title":"J Clin Invest"},{"key":"2802_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2021.680213","volume":"12","author":"MR Choi","year":"2021","unstructured":"Choi MR, Fern\u00e1ndez BE. Protective Renal Effects of Atrial Natriuretic Peptide: Where Are We Now? Front Physiol. 2021;12:680213.","journal-title":"Front Physiol"},{"key":"2802_CR22","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s40268-017-0191-y","volume":"17","author":"Y Nishida","year":"2017","unstructured":"Nishida Y, Takahashi Y, Tezuka K, Takeuchi S, Nakayama T, Asai S. Comparative Effect of Calcium Channel Blockers on Glomerular Function in Hypertensive Patients with Diabetes Mellitus. Drugs R D. 2017;17:403\u201312.","journal-title":"Drugs R D"},{"key":"2802_CR23","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1080\/08037051.2021.1996220","volume":"30","author":"D Zhang","year":"2021","unstructured":"Zhang D, Huang QF, Sheng CS, Li Y, Wang JG. Serum uric acid change in relation to antihypertensive therapy with the dihydropyridine calcium channel blockers. Blood Press. 2021;30:395\u2013402.","journal-title":"Blood Press"},{"key":"2802_CR24","doi-asserted-by":"publisher","first-page":"e035614","DOI":"10.1136\/bmjopen-2019-035614","volume":"10","author":"B Han","year":"2020","unstructured":"Han B, Wang N, Chen Y, Li Q, Zhu C, Chen Y, et al. Prevalence of hyperuricaemia in an Eastern Chinese population: a cross-sectional study. BMJ Open. 2020;10:e035614.","journal-title":"BMJ Open"}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41440-026-02802-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-026-02802-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-026-02802-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T23:03:59Z","timestamp":1793833439000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41440-026-02802-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,3]]},"references-count":24,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["2802"],"URL":"https:\/\/doi.org\/10.1038\/s41440-026-02802-6","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"value":"0916-9636","type":"print"},{"value":"1348-4214","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,3]]},"assertion":[{"value":"5 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"There are no conflicts of interest. No other disclosures were reported.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}}]}}